Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
Condition(s):Light Chain Deposition Disease; Primary Systemic AmyloidosisLast Updated:February 1, 2022Completed
Hide Studies Not Open or Pending
Condition(s):Light Chain Deposition Disease; Primary Systemic AmyloidosisLast Updated:February 1, 2022Completed
Condition(s):Gastrointestinal Dysfunction; Physiological Stress; Cognition – OtherLast Updated:July 21, 2023Completed
Condition(s):Renal Cell Carcinoma; MelanomaLast Updated:September 13, 2022Completed
Condition(s):Hemophilia BLast Updated:March 4, 2024Recruiting
Condition(s):Depression; Brain Injuries, TraumaticLast Updated:May 22, 2020Unknown status
Condition(s):Multiple MyelomaLast Updated:August 9, 2023Active, not recruiting
Condition(s):Metastatic MelanomaLast Updated:April 10, 2023Recruiting
Condition(s):Dental PlaqueLast Updated:February 28, 2022Completed
Condition(s):Breast CancerLast Updated:October 8, 2020Completed
Condition(s):Gingival Massage; Chronic PeriodontitisLast Updated:February 25, 2022Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.